LMO2 and acute lymphoblastic leukemia: Focusing on pediatric T-ALL, we analyzed the expression profiles of blast cells from the SET-NUP214 dataset [32] finding that MYCN-expressing samples were found almost exclusively in the TAL1+ subgroup (Fig. 1B), while the other molecular subgroups did not show almost any MYCN overexpression (mean expression ± 95% CI: 6.13 ± 0.25, TAL1+; 4.92 ± 0.35, TLX1+; 5.09 ± 0.13, TLX3+; 5.43 ± 0.42, LMO2+).